PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022. The presentation will update on three ongoing phase 2 clinical trials involving PDS0101, in collaboration with MERCK & Co., targeting head and neck cancer. Other trials include studies for advanced HPV-associated cancers and locally advanced cervical cancer, led by NCI and MD Anderson Cancer Center respectively. Additionally, updates on PDS0102 and PDS0103, focusing on various cancers, will be provided. A webcast replay will be available post-conference.

FLORHAM PARK, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune^® and Infectimune™ T-cell activating technologies respectively, today announced that its management will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022.

The presentation will provide an update on three ongoing PDS0101 phase 2 clinical trials. In the Versatile-002 phase 2 clinical trial, PDS Biotech is collaborating with MERCK & Co., to evaluate a combination of PDS0101 and KEYTRUDA^® (NCT04260126). Versatile-002 is studying the combination in first-line treatment of recurrent or metastatic head and neck cancer, and in second-line treatment of recurrent or metastatic head and neck cancer in patients who have failed prior checkpoint inhibitor therapy. In addition, the Company is conducting a phase 2 clinical study in both second- and third-line treatment of multiple advanced HPV-associated cancers. This study is being led by the National Cancer Institute (NCI). A third phase 2 clinical trial (IMMUNOCERV) in first-line treatment of locally advanced cervical cancer is being led by The University of Texas, MD Anderson Cancer Center.

The presentation will also provide updates on the progression of two other investigational pipeline immune-oncology products. PDS0102 (Versamune^® + TARP) addresses prostate cancer, breast cancer and AML, and PDS0103 (Versamune^® + MUC1) addresses multiple cancers including breast, colon, lung, and ovarian cancers. 

The conference is taking place virtually on January 28, 2022. Details for the presentation are as follows:

B. Riley Securities Virtual Oncology Conference
Date: Friday, January 28, 2022
Time: 12:30 pm ET
Investors can register for the conference HERE.

Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, PDS Biotechnology. 

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune^® and Infectimune™ T-cell activating technology platforms. Our Versamune^®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.  The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.  
Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contact:

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital 

FAQ

What are the latest updates on PDS Biotechnology's trials presented on January 28, 2022?

PDS Biotechnology will provide updates on three ongoing phase 2 trials involving PDS0101 for head and neck cancer, advanced HPV-associated cancers, and locally advanced cervical cancer.

Which companies are collaborating with PDS Biotechnology for their clinical trials?

PDS Biotechnology is collaborating with MERCK & Co. for the Versatile-002 phase 2 trial involving PDS0101 and KEYTRUDA.

What is the focus of the PDS0101 phase 2 clinical trials?

The PDS0101 trials focus on treating recurrent or metastatic head and neck cancer and advanced HPV-associated cancers.

Where can I watch the PDS Biotechnology conference presentation after January 28, 2022?

You can watch the webcast replay of the PDS Biotechnology presentation on the Investor section of their website.

What are PDS0102 and PDS0103 in PDS Biotechnology's pipeline?

PDS0102 and PDS0103 are investigational immune-oncology products targeting prostate cancer, breast cancer, AML, and multiple other cancers.